PE20060318A1 - Forma de administracion para la contracepcion hormonal - Google Patents

Forma de administracion para la contracepcion hormonal

Info

Publication number
PE20060318A1
PE20060318A1 PE2005000594A PE2005000594A PE20060318A1 PE 20060318 A1 PE20060318 A1 PE 20060318A1 PE 2005000594 A PE2005000594 A PE 2005000594A PE 2005000594 A PE2005000594 A PE 2005000594A PE 20060318 A1 PE20060318 A1 PE 20060318A1
Authority
PE
Peru
Prior art keywords
folic acid
administration
daily
hormone
units
Prior art date
Application number
PE2005000594A
Other languages
English (en)
Inventor
Georg Schramm
Eric-Paul Paques
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004026670A external-priority patent/DE102004026670A1/de
Priority claimed from DE102004026671A external-priority patent/DE102004026671A1/de
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20060318A1 publication Critical patent/PE20060318A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA DE ADMINISTRACION ORAL DIARIA ININTERRUMPIDA, QUE CONSISTE EN: A) AL MENOS 21 A 25 UNIDADES DIARIAS DE HORMONAS CARACTERIZADAS POR COMBINACION DE ESTROGENOS TALES COMO ESTRADIOL, VALERATO DE ESTRADIOL, MESTRANOL, ETINILESTADIOL; GESTAGENO SELECCIONADO DE NORGESTREL, GESTODEN, NORETISTERONA, NORGESTIMAT, ENTRE OTROS; Y ACIDO FOLICO ENTRE 5-200 ug; B) 7 A 3 UNIDADES DIARIAS DE UNA CANTIDAD MAYOR DE 200 ug DE ACIDO FOLICO, HASTA LA CANTIDAD MAXIMA ADMITIDA PARA MUJERES. DICHA FORMA DE ADMINISTRACION PERMITE EQUIPAR CON ACIDO FOLICO LA FORMULACION, TOMANDO EN CUENTA LOS DIFERENTES REQUERIMIENTOS DE ACIDO FOLICO DURANTE EL CICLO DE ADMINISTRACION DE HORMONAS Y DURANTE UNA TOMA POSTRIOR DE UNIDADES DIARIAS QUE NO CONTIENEN HORMONAS, SIENDO UTILES EN LA ANTICONCEPCION HORMONAL
PE2005000594A 2004-05-28 2005-05-27 Forma de administracion para la contracepcion hormonal PE20060318A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004026670A DE102004026670A1 (de) 2004-05-28 2004-05-28 Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A DE102004026671A1 (de) 2004-05-28 2004-05-28 Darreichungsform zur hormonalen Kontrazeption

Publications (1)

Publication Number Publication Date
PE20060318A1 true PE20060318A1 (es) 2006-06-15

Family

ID=34969970

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000594A PE20060318A1 (es) 2004-05-28 2005-05-27 Forma de administracion para la contracepcion hormonal

Country Status (9)

Country Link
EP (2) EP1755562B1 (es)
AR (1) AR049065A1 (es)
DK (1) DK1755562T3 (es)
ES (1) ES2438734T3 (es)
PE (1) PE20060318A1 (es)
PL (1) PL1755562T3 (es)
PT (1) PT1755562E (es)
SI (1) SI1755562T1 (es)
WO (1) WO2005115349A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005053771A1 (de) 2005-11-09 2007-05-10 Grünenthal GmbH Darreichform zur hormonalen Kontrazeption
JP2009542588A (ja) * 2006-07-06 2009-12-03 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 避妊及び先天的異常の危険性の予防のための医薬製剤
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
ME03728B (me) 2015-06-18 2021-01-20 Estetra Sprl Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola
RS61777B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetrol
SI3310345T1 (sl) 2015-06-18 2021-05-31 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB888631A (en) * 1959-02-24 1962-01-31 Upjohn Co Improvements in or relating to oral therapeutic compositions comprising steroids
EP2002839A1 (en) 1998-04-17 2008-12-17 Ortho McNeil Pharmaceutical, Inc. Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
US6911438B2 (en) * 2001-09-12 2005-06-28 Jonathan V. Wright Hormone replacement formulation

Also Published As

Publication number Publication date
ES2438734T3 (es) 2014-01-20
DK1755562T3 (da) 2013-12-16
PT1755562E (pt) 2013-12-26
SI1755562T1 (sl) 2014-02-28
EP1755562A1 (de) 2007-02-28
EP2263659A1 (de) 2010-12-22
EP1755562B1 (de) 2013-10-09
AR049065A1 (es) 2006-06-21
WO2005115349A1 (de) 2005-12-08
PL1755562T3 (pl) 2014-03-31

Similar Documents

Publication Publication Date Title
PE20060318A1 (es) Forma de administracion para la contracepcion hormonal
ES2561810T3 (es) Antagonistas de progesterona tales como CDB-4124 para reducir el dolor asociado a endometriosis y fibroides uterinos
EP2512486B1 (en) Nestorone®/estradiol transdermal gel
PE20070188A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
PE20080273A1 (es) Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
PE20070208A1 (es) Anticoncepcion oral con trimegestona
PE20070327A1 (es) Composicion que comprende una progestina y un estrogeno
BRPI0400214A (pt) Composições e aplicações farmacêuticas para a obtenção confiável de nìveis aceitáveis de testosterona no soro
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
RS20060348A (en) Extended use combination comprising estrogens and progestins
AU2012293593A8 (en) Use of estetrol as emergency contraceptive
JP2013018787A5 (es)
CR7022A (es) Productos esteroides hormonales y metodos para su preparacion
CR7420A (es) Composiciones farmaceuticas que comprenden uno o varios esteroides, uno o varios componentes de tetrahiidrofolatos y vitamina b12
MEP38008A (en) Drospirenone for hormone replacement therapy
PE20061415A1 (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
BR112014031914A2 (pt) cápsula de estradiol solúvel para inserção vaginal
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
AR061959A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
AR065816A1 (es) Regimen anticonceptivo oral
ES2208518T3 (es) Medio y metodo anticonceptivo hormonal.
TW200612962A (en) Estriol and estetrol prodrugs
MX2010001370A (es) Composiciones que comprenden agonista del receptor glucocorticoide disociado para tratar o controlar inflamacion del segmento anterior.
ECSP109872A (es) Estratrienos 8-beta-sustituidos como estrógenos de acción selectiva
DK2366395T1 (da) Anvendelse af et østrogen til fremstillingen af en sammensætning indeholdende østrogen til behandlingen af atrofisk vaginitis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal